(trade name)


Therapeutic: bronchodilators
Pharmacologic: beta adrenergic agonists
Pregnancy Category: C


Maintenance treatment of airflow obstruction in patients with COPD including chronic bronchitis and emphysema.


A long-acting beta2-adrenergic agonist (LABA) that stimulates adenyl cyclase, resulting in accumulation of cyclic adenosine monophosphate (cAMP) at beta2-adrenergic receptors resulting in bronchodilation.

Therapeutic effects

Bronchodilation with decreased airflow obstruction.


Absorption: 30% absorbed following oral inhalation (from lung surface); swallowed drug is minimally absorbed.
Distribution: Extensive tissue distribution; probably enters breast milk.
Metabolism and Excretion: Extensively metabolized (some by CYP 3A4), only one metabolite binds to B2adrenergic receptors. Following inhalation, 5–7% excreted unchanged in urine, remainder in feces as drug and metabolites (84%).
Half-life: 45 hr (following inhalation).

Time/action profile (improvement in FEV1)

inhalnwithin 1 hr1–5 hr24 hr


Contraindicated in: Severe/acute/deteriorating symptoms of airflow obstruction.
Use Cautiously in: History of seizures; Thyrotoxicosis; History of cardiovascular disorders (coronary insufficiency, arrhythmias, hypertension); Sensitivity to sympathomimetics (adrenergics); Severe hepatic impairment; Obstetric: Use during pregnancy only if potential benefit justifies potential risk to the fetus; Lactation: Use cautiously if breastfeeding (probably enters breast milk); Pediatric: Safe and effective use in children has not been established.
Exercise Extreme Caution in: Concurrent use with MAOIs, tricyclic antidepressants or drugs that prolong QTc (↑ risk of adverse cardiovascular reactions).

Adverse Reactions/Side Effects

Central nervous system

  • dizziness

Ear, Eye, Nose, Throat

  • nasopharyngitis (most frequent)


  • paradoxical bronchospasm (life-threatening)
  • cough


  • ↑ BP
  • ECG changes
  • tachycardia


  • diarrhea


  • hyperglycemia

Fluid and Electrolyte

  • hypokalemia


  • arthralgia
  • back pain


  • hypersensitivity reactions including angioedema (life-threatening)


Drug-Drug interaction

Concurrent use with MAOIs, tricyclic antidepressants, or drugs that prolong QTc ↑ risk of adverse cardiovascular reactions (use with extreme caution). Concurrent use of other adrenergics ↑ risk of adverse adrenergic adverse reactions (tachycardia, ↑ blood pressure). Concurrent use with corticosteroids, non-potassium sparing diuretics, or xanthine derivatives (including theophylline) may ↑ risk of hypokalemia and adverse cardiovascular reactions (use cautiously). Concurrent use with beta blockers may ↓ effectiveness and cause severe bronchospasm (use cautiously). Should not be used concurrently with any other long-acting beta2-adrenergic blockers (LABAs)Blood levels may be ↑ by ketoconazole.


Inhalation (Adults) 2 inhalations once daily.


Inhalation spray: 2.7 mcg (delivers 2.5 mcg) per actuation in cartridges containing 14 doses/cartridge (one actuation lost in priming) for use with Respimat inhaler

Nursing implications

Nursing assessment

  • Assess respiratory status (rate, breath sounds, degree of dyspnea, pulse) before administration and at peak of medication. Consult health care professional about alternative medication if severe bronchospasm is present; onset of action is too slow for patients in acute distress. If paradoxical bronchospasm (wheezing) occurs, withhold medication and notify health care professional immediately.
  • Monitor for signs and symptoms of allergic reactions (difficulties in breathing or swallowing, swelling of tongue, lips and face, urticaria, skin rash). Discontinue therapy if symptoms occur.
  • Lab Test Considerations: May cause transient hypokalemia and hyperglycemia.

Potential Nursing Diagnoses

Ineffective airway clearance (Indications)
Risk for activity intolerance (Indications)


  • Inhalation: Prior to first use, prime the inhaler by actuating toward ground until aerosol cloud is visible, then repeat procedure 3 more times. If not used for 3 days, actuate inhaler once to prepare for use. Striverdi Respimat has a slow-moving mist to assist with inhalation. Use once (2 puffs), at the same time daily.
    • A rescue inhaler of short-acting beta2-agonists should always be available to treat sudden bronchospasm.

Patient/Family Teaching

  • Instruct patient in the correct use of Striverdi Respimat. Take missed doses as soon as remembered. Do not take more than 1 dose (2 puffs) in 24 hr. Advise patient not to discontinue without consulting health care professional; symptoms may recur.
  • Inform patient that olodaterol is not an rapid-actinga long-acting bronchodilator and should not be used for treating sudden breathing problems.
  • Advise patient to notify health care professional if signs and symptoms of allergic reaction, worsening symptoms; decreasing effectiveness of inhaled, short-acting beta2–agonists; need for more inhalations than usual of inhaled, short-acting beta2-agonists; or significant decrease in lung function occur.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to avoid concurrent use of Rx, OTC, and herbal products without consulting health care professional.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

  • Bronchodilation with decreased airflow obstruction.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
Clinical review report: tiotropium bromide monohydrate and olodaterol hydrochloride (Inspiolto Respimat) for oral inhalation for the long-term, once daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema [Internet].
German pharmaceutical company Boehringer Ingelheim reported on Thursday the receipt of approval from the US Food and Drug Administration (FDA) for new labeling for Stiolto Respimat (tiotropium bromide & olodaterol) Inhalation Spray for reduction in COPD exacerbations, including chronic bronchitis and emphysema.
Bronchodilators, which improve lung function, decrease hyperinflation, and improve exercise performance by decreasing airway smooth muscle tone, are the cornerstone of COPD treatment and include short- and long-acting [[beta].sub.2]-agonists (SABAs [eg, albuterol/salbutamol and levalbuterol] and LABAs [eg, formoterol, indacaterol, olodaterol, and salmeterol]), and shortand long-acting muscarinic antagonists (SAMAs [eg, ipratropium bromide] and LAMAs [eg, aclidinium, glycopyrronium bromide, umeclidinium, and tiotropium]).
Neither heart rate nor blood pressure worsened under long-term use of long-acting [beta.sub.2] agonists olodaterol or formoterol in patients with chronic obstructive pulmonary disease, according to a post hoc pooled analysis published in Pulmonary Pharmacology & Therapeutics.
In addition, we will summarize important clinical examples (albuterol, fluticasone propionate/budesonide, and olodaterol) that clearly demonstrate the complex interplay between pulmonary PK processes and factors related to the drug, formulation and device, and patients.
Boehringer Ingelheim announced that the Food and Drug Administration approved once-daily Stiolto Respimat (tiotropium bromide and olodaterol) inhalation spray as a long-term, once-a-day maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Three drugs are classified as respiratory agents: nintedanib (Ofev), olodaterol (Striverdi Respimat), and pirfenidone (Esbriet).
Olodaterol is a long-acting beta-adrenergic agonist for use in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphy sema.
Boehringer Ingelheim's New Drug Application (NDA) has been accepted by the FDA for the fixed-dose combination (FDC) of tiotropium and olodaterol delivered via the Respimat inhaler for the proposed indication of long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
The latest drugs available in the [[beta].sub.2] category are the longer-acting [[beta].sub.2] agonists--the ultra-LABAs--and include indacaterol, carmoterol, vilanterol and olodaterol. All of the ultra-LABAs have a duration of action greater than 24 hours and are suitable for once-daily dosing.